Combined use of CA 19-9 and CEMIP significantly increased the sensitivity and specificity in discriminating not only patients with all stage pancreatic cancer but also patients with stage I/II pancreatic cancer from healthy individuals. The gene discussed is CEMIP; the disease is familial pancreatic carcinoma.